Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $1.4M
- Net income
- -$62.4M
- Total assets
- $18.6M
- Market cap
- $262.7M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $262.7M
- Shares outstanding
- 505.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2016
Outlook Therapeutics, Inc. (OTLK) Stock Price
- Reported a net loss of $62.4M in FY2025.
- Trading 79% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Outlook Therapeutics, Inc..
Write a review
News about Outlook Therapeutics, Inc.
News & sentiment via Polygon.io
Outlook Therapeutics, Inc.: frequently asked questions
Is Outlook Therapeutics, Inc. an American company?
Outlook Therapeutics, Inc. is a US-based company headquartered in Iselin, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc. is headquartered in Iselin, New Jersey, United States.
Is Outlook Therapeutics, Inc. publicly traded?
Yes — Outlook Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol OTLK on the NASDAQ.
What does Outlook Therapeutics, Inc. do?
Outlook Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
